The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories (NYSE:FRX) under the brand name Celexa, as a potential way to help slow down the development of Alzheimer's disease.
Now this study was small and further research needs to be done, but it shows that anti-depressent use may reduce the production of beta-amyloid plaques, seen as a contributing factor for the development of Alzheimer's. However, there is a long way to go and a lot of science to discover before these common drugs are seen as a preventative tool for those at risk.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss this trial, how our knowledge of the disease is evolving and the many other new Alzheimer's treatments being developed right now.
David Williamson owns shares of Johnson & Johnson and Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Did Forest Laboratories Buy Furiex Pharmaceuticals?
Forest Laboratories bought Furiex Pharmaceuticals. Smart move?
Why Furiex Pharmaceuticals Inc. Shares Skyrocketed
Furiex shares soar after agreeing to be purchased by Forest Labs. Find out if this is a smart move or wasted money on Forest Labs' part.
Monday’s Top Health Care Stories: Pfizer, AstraZeneca, Mylan, Forest, and Furiex
Keep a close eye on Pfizer, AstraZeneca, Mylan, Forest, and Furiex this morning.